openPR Logo
Press release

Pancreatic Cancer Pipeline Drugs Review H1 2017

07-06-2017 02:24 PM CET | Health & Medicine

Press release from: ReportsandReports

Pancreatic Cancer Pipeline Review H1 2017 provides an overview of the Pancreatic Cancer (Oncology) therapeutics pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

For More on Pancreatic Cancer Pipeline Review H1 2017 report inquire @ https://tinyurl.com/Pancreatic-Cancer-Pipeline .

Report Description:

Pharmaceutical guide Pancreatic Cancer - Pipeline Review H1 2017 guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type and reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.

The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Get Discount on Report@ https://tinyurl.com/Pancreatic-Cancer-Therapeutics .

Report Includes Pancreatic Cancer Pipeline by Companies:

3-V Biosciences Inc, 4P-Pharma SAS, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Actuate Therapeutics Inc, Adamed Sp z oo, Aduro BioTech Inc, Advanced Cancer Therapeutics LLC, Advantagene Inc, Agenus Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alissa Pharma, Allinky Biopharma, Almac Discovery Ltd, Altor BioScience Corp, Ambrx Inc, amcure GmbH, American Gene Technologies International Inc, Amgen Inc, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Aphios Corp, APIM Therapeutics AS, Apogenix GmbH, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, Autotelic Inc, AVEO Pharmaceuticals Inc, Axcentua Pharmaceuticals AB, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene (Beijing) Co Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio ASA, Beta Pharma Inc, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, BioLineRx Ltd, Biomar Microbial Technologies, Biomunex Pharmaceuticals, Bioncotech Therapeutics SL, Bionomics Ltd, BioNTech AG, Biotest AG, Biouniversa srl, BLR Bio LLC, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd, Calithera Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Cantargia AB, Cascadian Therapeutics Inc, Cavion LLC, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celleron Therapeutics Ltd, Cellular Biomedicine Group Inc, Celprogen Inc, Celyad SA, Centrose LLC, Ceronco Biosciences, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology Inc, COARE Biotechnology Inc, Codiak BioSciences Inc, Concordia International Corp, Confluence Life Sciences Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, Cytori Therapeutics Inc, CytRx Corp, CyTuVax BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, DEKK-TEC Inc, Denceptor Therapeutics Ltd, Diffusion Pharmaceuticals Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endor Nanotechnologies SL, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, FibroGen Inc, Formosa Laboratories Inc, Forty Seven Inc, Fountain Biopharma Inc, Fujifilm Corp, Fusion Antibodies Ltd, Galena Biopharma Inc, GamaMabs Pharma SA, Geistlich Pharma AG, Genelux Corp, Genentech Inc, Genisphere LLC, Genmab A/S, Gilead Sciences Inc, GlaxoSmithKline Plc, Globeimmune Inc, GlycoMimetics Inc, Glycotope GmbH, Golden Biotechnology Corp, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, Helix BioPharma Corp, Horizon Pharma Plc, Humorigin Biotechnology Corp, iCeutica Inc, Idera Pharmaceuticals Inc, Igenica Biotherapeutics Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune Pharmaceuticals Inc, Immune System Key Ltd, Immune Therapeutics Inc, Immunitor Inc, Immunomedics Inc, Immunotope Inc, Immunovo BV, Immupharma Plc, Incyte Corp, Inflection Biosciences Ltd, Innopharmax Inc, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Intezyne Technologies Inc, Inventiva, InvivoGen Therapeutics, Io Therapeutics Inc, Ipsen SA, ISU ABXIS Co Ltd, Jasco Pharmaceuticals LLC, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kalyra Pharmaceuticals Inc, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics Inc, Keystone Nano Inc, Komipharm International Co Ltd, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Lidds AB, Lion Biotechnologies Inc, Lipopharma Therapeutics SL, Lixte Biotechnology Holdings Inc, Loxo Oncology Inc, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, Mebiopharm Co Ltd, MediaPharma Srl, Medicenna Therapeutics Corp, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Millennium Pharmaceuticals Inc, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, Mount Tam Biotechnologies Inc, NanoCarrier Co Ltd, NantKwest Inc, Nascent Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, NBE-Therapeutics AG, Nerviano Medical Sciences Srl, NewLink Genetics Corp, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Novogen Ltd, Novus Therapeutics Inc, Noxxon Pharma AG, NuCana BioMed Ltd, OBI Pharma Inc, Omeros Corp, Oncodesign SA, Oncolytics Biotech Inc, Oncomatryx Biopharma SL, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, Orega Biotech SAS, Oribase Pharma, Oryx GmbH & Co KG, Patrys Ltd, Pfizer Inc, Pharma Two B Ltd, PharmAbcine Inc, PharmaCyte Biotech Inc, Pharmedartis GmbH, Phoenix Biotechnology Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Prima BioMed Ltd, Propanac Biopharma Inc, Provectus Biopharmaceuticals Inc, Puretech Health plc, Quest PharmaTech Inc, Quimatryx SL, Quintessence Biosciences Inc, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Samumed LLC, Samyang Holdings Corp, Sanofi, Sareum Holdings Plc, SATT North SAS, Selecta Biosciences Inc, Sierra Oncology Inc, SignPath Pharma Inc, Sillajen Biotherapeutics, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Spring Bank Pharmaceuticals Inc, Stelic Institute & Co Inc, Strongbridge Biopharma plc, Sumitomo Dainippon Pharma Co Ltd, Sun BioPharma Inc, Sun Pharma Advanced Research Company Ltd, Sunshine Biopharma Inc, Swedish Orphan Biovitrum AB, Symic Biomedical Inc, Symphogen A/S, SynCore Biotechnology Co Ltd, Synergys Biotherapeutics Inc, Synovo GmbH, SyntheX Inc, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takara Bio Inc, Takeda Pharmaceutical Company Ltd, Takis Srl, Targovax ASA, Tarveda Therapeutics Inc, tella Inc, Threshold Pharmaceuticals Inc, Tiltan Pharma Ltd, Tocagen Inc, Tolero Pharmaceuticals Inc, Transcriptogen Ltd, Transgene SA, TVAX Biomedical Inc, Tyg Oncology Ltd, Tyme Technologies Inc, Tyrogenex Inc, UbiVac LLC, ValiRx Plc, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, Vaximm AG, Vaxon Biotech, VCN Biosciences SL, Vect-Horus SAS, Verastem Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, ViiV Healthcare Ltd, Viralytics Ltd, Virobay Inc, ViroStatics srl, Wilex AG, Zeria Pharmaceutical Co Ltd.

Scope:

-The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology).
Purchase This Report at: https://tinyurl.com/Pancreatic-Cancer-Drugs .

Major Table of Content:

• Introduction
• Pancreatic Cancer - Overview
• Pancreatic Cancer - Therapeutics Development
• Pancreatic Cancer - Therapeutics Assessment
• Pancreatic Cancer - Companies Involved in Therapeutics Development
• Pancreatic Cancer - Drug Profiles
• Pancreatic Cancer - Dormant Projects
• Pancreatic Cancer - Discontinued Products
• Pancreatic Cancer - Product Development Milestones.

Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@reportsnreports.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Cancer Pipeline Drugs Review H1 2017 here

News-ID: 612618 • Views: 2492

More Releases from ReportsandReports

Pharmaceutical Processing Seals Market Grow By Leading Industry Players Trellebo …
According to Market Study Report, Pharmaceutical Processing Seals Market provides a comprehensive analysis of the Pharmaceutical Processing Seals Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1994008 The Pharmaceutical Processing Seals Market is estimated to be USD 1.8 Billion in 2018 and is projected to reach USD 2.4 Billion by 2023, at a CAGR of 6.0%. This
Aliphatic Hydrocarbon Solvents & Thinners Market Expected to Grow at 5.2 Billion …
According to Market Study Report, Aliphatic Hydrocarbon Solvents & Thinners Market provides a comprehensive analysis of the Aliphatic Hydrocarbon Solvents & Thinners Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=453969 The Aliphatic Hydrocarbon Solvents & Thinners Market is projected to grow from USD 4.6 billion in 2019 to USD 5.2 billion by 2024, at a CAGR
Immunoprecipitation Market to Witness Huge Growth by Key Players: Thermo Fisher …
According to Market Study Report, Immunoprecipitation Market provides a comprehensive analysis of the Immunoprecipitation Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1935712 The Immunoprecipitation Market is projected to reach USD 750 Million by 2024 from USD 560 Million in 2018, at CAGR of 5.0% during forecast period. This report spread across 113 Pages, Profiling 10 Companies
Recent Analysis of Environmental Testing Equipment Market | Agilent Technologies …
According to Market Study Report, Environmental Testing Equipment Market provides a comprehensive analysis of the Environmental Testing Equipment Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1897839 The Global Environmental Testing Equipment Market is projected to reach 2.9 billion by 2023 from USD 2.1 billion in 2018 at a CAGR of 7.1%. This report spread across 161

All 5 Releases


More Releases for Pharma

Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Clomifene Citrate Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Clomifene Citrate Market" across the global, regional and country level. The report provides 360° analysis of "Clomifene Citrate Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Clomifene Citrate industry, and estimates the future trend of Clomifene Citrate market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business